פיברוגאמין 250IU FXIII - Fibrogammin 250 iu fxiii
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | B02BD Blood coagulation factors | |||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||||||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | |||||||||||||
| צ×רת ××× ×× | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/SOLU ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||||||||||
| ×ת×××× | Fibrogammin is indicated for adult and paediatric patients ⢠for prophylactic treatment of congenital FXIII deficiency and ⢠for peri-operative management of surgical bleeding with congentital FXIII deficiency. Fibrogammin is furthermore indicated ⢠for haemorrhagic diatheses caused completely or in part by acquired FXIII deficiency ⢠for supportive therapy in case of disturbance in wound healing, especially in ulcus cruris, after large surgery or injuries. | |||||||||||||
| ||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר×פ×
| |||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| פ××ר×××××× 250IU FXIII ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | CSL BEHRING GmbH, GERMANY |
| ×©× ××¢× ×ר×ש×× | CSL BEHRING LTD., ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 4/1997. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־23 בפברואר 2024 ב־15:38